ReviewGastroenterology research and practice2017
A Meta-Analysis and Systematic Review of the Efficacy of Twice Daily PPIs versus Once Daily for Treatment of Gastroesophageal Reflux Disease.
Review in Gastroenterology research and practice, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Thailand guideline 2020 for medical management of gastroesophageal reflux disease.Journal of gastroenterology and hepatology · 2022Guideline
- Potassium-competitive acid blockers and proton-pump inhibitors for the healing and maintenance of erosive esophagitis: a comprehensive and updated systematic review with network meta-analysis.Esophagus : official journal of the Japan Esophageal Society · 2026Review
- Acid peptic disorder compass: An Indian expert consensus on comprehensive management.World journal of gastrointestinal pharmacology and therapeutics · 2026Review
- Gastroesophageal Reflux Disease in the World Trade Center Health Program General Responder Cohort.American journal of industrial medicine · 2025Article
- The Impact of a Twice-daily Versus Once-daily Proton Pump Inhibitor Dosing Regimen on Laryngopharyngeal Reflux Symptoms: A Prospective Randomized Controlled Trial.Journal of neurogastroenterology and motility · 2024Article
- Long-Term Proton Pump Inhibitor-Acid Suppressive Treatment Can Cause Vitamin BInternational journal of molecular sciences · 2024Article
- Efficacy and safety of Jianpi Qinghua granules for non-erosive reflux disease with spleen deficiency and damp-heat syndrome: a multicenter, randomized, double-blind, placebo-controlled clinical trial.Frontiers in nutrition · 2024Article
- Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux disease.The Lancet. Rheumatology · 2022Article
- Review
- Survey-Based Analysis of Current Trends for Prescribing Gastrointestinal Protectants among Small-Animal General Practitioners in Portugal.Veterinary sciences · 2021Article
- Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors.The American journal of gastroenterology · 2020Article
- Indian consensus on gastroesophageal reflux disease in adults: A position statement of the Indian Society of Gastroenterology.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo investigate whether PPIs BID is superior to QD for treatment of GERD in a short time.
methodsWe searched PubMed, Cochrane Library, Scopus, EMBASE, Ovid, EBSCO, and Web of Science databases (from 1998 to May 2016) to select RCTs, which compared the efficacy of PPIs BID versus QD for GERD. The primary outcomes were symptom relief or esophageal mucosal healing at weeks 4 and 8. The M-H method with fixed-effect or random-effect model was used to calculate RR and 95% CIs.
resultsSeven RCTs were enrolled. The esophageal healing rates were higher in PPIs BID group (
conclusionPPIs BID more effectively improve endoscopic healing rate at week 8 than PPIs QD. But there are no significant differences in symptom relief, 24 h pH monitoring, sustained symptom relief, and endoscopic response at week 4.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.